Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

Author:

O'Donnell Peter H.1ORCID,Milowsky Matthew I.2ORCID,Petrylak Daniel P.3ORCID,Hoimes Christopher J.4ORCID,Flaig Thomas W.5ORCID,Mar Nataliya6ORCID,Moon Helen H.7,Friedlander Terence W.8ORCID,McKay Rana R.9ORCID,Bilen Mehmet A.10ORCID,Srinivas Sandy11,Burgess Earle F.12ORCID,Ramamurthy Chethan13ORCID,George Saby14ORCID,Geynisman Daniel M.15ORCID,Bracarda Sergio16ORCID,Borchiellini Delphine17,Geoffrois Lionnel18,Maroto Rey Jose Pablo19,Ferrario Christiano20,Carret Anne-Sophie21ORCID,Yu Yao21,Guseva Maria22,Homet Moreno Blanca23,Rosenberg Jonathan E.24ORCID

Affiliation:

1. University of Chicago, Chicago, IL

2. University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC

3. Yale Cancer Center, New Haven, CT

4. Duke Cancer Institute, Duke University, Durham, NC

5. University of Colorado Comprehensive Cancer Center, Aurora, CO

6. University of California at Irvine, Irvine, CA

7. Kaiser Permanente Southern California, Riverside, CA

8. University of California at San Francisco, San Francisco, CA

9. University of California at San Diego, San Diego, CA

10. Emory University Winship Cancer Institute, Atlanta, GA

11. Stanford Cancer Center, Stanford, CA

12. Levine Cancer Center, Charlotte, NC

13. University of Texas Health Sciences Center at San Antonio, San Antonio, TX

14. Roswell Park Cancer Center, Buffalo, NY

15. Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA

16. Azienda Ospedaliera Santa Maria di Terni, Terni, Italy

17. Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France

18. Institut de Cancerologie de Lorraine, Vandoeuvre Les Nancy, France

19. Hospital de la Santa Creu i Sant Paul, Barcelona, Spain

20. Jewish General Hospital, Montreal, Quebec, Canada

21. Seagen Inc, Bothell, WA

22. Astellas Pharma, Northbrook, IL

23. Merck & Co Inc, Rahway, NJ

24. Memorial Sloan Kettering Cancer Center, New York, NY

Abstract

PURPOSE Patients with locally advanced or metastatic urothelial cancer (la/mUC) who are ineligible for cisplatin-based therapy have limited first-line (1L) treatment options and significant need for improved therapies. Enfortumab vedotin (EV) and pembrolizumab (Pembro) individually have shown a survival benefit in urothelial cancer in second-line + la/mUC settings. Here, we present data from the pivotal trial of EV plus Pembro (EV + Pembro) in the 1L setting. PATIENTS AND METHODS In Cohort K of the EV-103 phase Ib/II study, cisplatin-ineligible patients with previously untreated la/mUC were randomly assigned 1:1 to receive EV as monotherapy or in combination with Pembro. The primary end point was confirmed objective response rate (cORR) per blinded independent central review. Secondary end points included duration of response (DOR) and safety. There were no formal statistical comparisons between treatment arms. RESULTS The cORR was 64.5% (95% CI, 52.7 to 75.1) and 45.2% (95% CI, 33.5 to 57.3) for patients treated with EV + Pembro (N = 76) and EV monotherapy (N = 73), respectively. The median DOR was not reached for the combination and was 13.2 months for monotherapy; 65.4% and 56.3% of patients who responded to the combination and monotherapy, respectively, maintained a response at 12 months. The most common grade 3 or higher treatment-related adverse events (TRAEs) in patients treated with the combination were maculopapular rash (17.1%), fatigue (9.2%), and neutropenia (9.2%). EV TRAEs of special interest (any grade) in the combination arm included skin reactions (67.1%) and peripheral neuropathy (60.5%). CONCLUSION EV + Pembro showed a high cORR with durable responses as 1L treatment in cisplatin-ineligible patients with la/mUC. Patients who received EV monotherapy had a response and safety profile consistent with previous studies. Adverse events for EV + Pembro were manageable, with no new safety signals observed.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3